Safety Study of P28GST Treatment in Crohn's Disease Patients
Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
This multicenter phase 2 clinical trial is designed to assess safety of P28GST (protein 28 Kd
glutathion S Transferrase), aiming to control inflammation in moderate Crohn's Disease (CD),
before or after intestinal resection surgery. P28GST is a parasite enzyme molecule from
Schistosoma with potent immunogenic and anti-oxidant properties. Based on experimental
evidence of its anti-inflammatory properties, the investigators hypothesized that
administration of P28GST could protect against recurrence after intestinal resection surgery
in CD.